Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18646759 | 0.85 | MAPK1 (0.57) | MAPK1HSD17B10PKMATMCA12 | |
| SCHEMBL10703847 | 0.81 | MAPK1 (0.49) | MAPK1HSD17B10PKMATMCA12 | |
| SCHEMBL8004671 | 0.80 | MAPK1 (0.47) | MAPK1HSD17B10PKMATMCA12 | |
| SCHEMBL1779273 | 0.79 | MAPK1 (0.46) | MAPK1HSD17B10PKMATMCA12 | |
| SCHEMBL18839760 | 0.78 | MAPK1 (0.56) | MAPK1HSD17B10PKMATMCA12 | |
| SCHEMBL7507078 | 0.77 | MAPK1 (0.49) | MAPK1HSD17B10PKMATMALDH1A1 | |
| SCHEMBL2440580 | 0.76 | MAPK1 (0.51) | MAPK1HSD17B10PKMATMCA12 | |
| SCHEMBL10612564 | 0.76 | ALDH1A1 (0.36) | HSD17B10ALDH1A1SMN1; SMN2GAARAB9A | |
| SCHEMBL3088954 | 0.76 | MAPK1 (0.40) | MAPK1HSD17B10PKMATMALDH1A1 | |
| SCHEMBL18605497 | 0.75 | MAPK1 (0.50) | MAPK1HSD17B10PKMATMCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002355-A1 | PROCESS FOR THE MANUFACTURE OF TETRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-04 | — | — | US | disclosed |
| EP-4247799-A1 | NEW PROCESS FOR THE MANUFACTURE OF TETRAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-09-27 | — | — | EP | disclosed |
| CN-116635372-A | Novel process for producing tetrazole derivatives | 豪夫迈·罗氏有限公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2022106669-A1 | NEW PROCESS FOR THE MANUFACTURE OF TETRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022106669-A1 | NEW PROCESS FOR THE MANUFACTURE OF TETRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-27 | — | — | WO | disclosed |
| US-20220030868-A1 | FUNGICIDAL HALOMETHYL KETONES AND HYDRATES | FMC CORPORATION | 2022-02-03 | — | — | US | disclosed |
| WO-2020056090-A1 | FUNGICIDAL HALOMETHYL KETONES AND HYDRATES | FMC CORPORATION (US) | 2020-03-19 | — | — | WO | disclosed |
| EP-1896394-B1 | SUBSTITUTED ENAMINONES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2013-05-29 | — | — | EP | disclosed |
| US-7820663-B2 | Substituted enaminones, their derivatives and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-26 | — | — | US | disclosed |
| EP-1896394-A1 | SUBSTITUTED ENAMINONES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | The Regents of the University of California (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060293329-A1 | Substituted enaminones, their derivatives and uses thereof | OXFORD FINANCE CORPORATION | 2006-12-28 | — | — | US | disclosed |
| WO-2006138510-A1 | SUBSTITUTED ENAMINONES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-28 | — | — | WO | disclosed |
| US-5110940-A | Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase | BRISTOL-MYERS COMPANY (US) | 1992-05-05 | — | — | US | disclosed |
| US-5068346-A | Anticholesterol agents | BRISTOL-MYERS COMPANY (US) | 1991-11-26 | — | — | US | disclosed |
| US-4939265-A | Intermediates and process for the preparation of antihypercholesterolemic tetrazole compounds | BRISTOL-MYERS COMPANY (US) | 1990-07-03 | — | — | US | disclosed |
| US-4898949-A | Intermediates for the preparation of antihypercholesterolemic tetrazole compounds | BRISTOL-MYERS COMPANY (US) | 1990-02-06 | — | — | US | disclosed |
| US-4897490-A | DERIVATIVES OF BETA-HYDROXY,OMEGA-DIPHENYL,TETRAZOL-5-YL ALK-OMEGA-ENOIC ACID, ESTER OR LACTONE | BRISTOL-MEYERS COMPANY (US) | 1990-01-30 | — | — | US | disclosed |
| WO-1988006584-A1 | ANTIHYPERCHOLESTEROLEMIC TETRAZOLE COMPOUNDS | BRISTOL-MYERS COMPANY (US) | 1988-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220030868-A1 | FUNGICIDAL HALOMETHYL KETONES AND HYDRATES | TUBA1A, TTBK1, TUBA1B | MAPK1 2179/4885HSD17B10 353/4885PKM 165/4885 |
| US-20240002355-A1 | PROCESS FOR THE MANUFACTURE OF TETRAZOLE DERIVATIVES | CYP2F1, CYP1A2, CYP3A4 | MAPK1 2872/4885HSD17B10 1125/4885PKM 671/4885 |
| US-20060293329-A1 | Substituted enaminones, their derivatives and uses thereof | CHRNA7, CHRNA5, CHRNA1 | MAPK1 1330/4885HSD17B10 2091/4885PKM 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.